Evofem Biosciences Added Second PHEXX Manufacturer

The company secured a secondary manufacturing source to lower production costs for its hormone-free vaginal gel.

Updated on Sept. 23, 2026 in Sex Life

Bold vector editorial illustration of a single clean pharmaceutical vial in a sterile workspace, representing hormone-free healthcare manufacturing innovation. — Evofem Biosciences has contracted a second manufacturer for its PHEXX contraceptive gel, a move expected to reduce production costs and improve supply chain stability. AI Illustration. Upload story photo >

Live Poll

Do you trust pharmaceutical companies to pass manufacturing cost savings on to consumers?

San Diego-based Evofem Biosciences has contracted a second pharmaceutical manufacturer to produce PHEXX. This strategic move aims to enhance the company's manufacturing flexibility and lower unit costs for the contraceptive gel.

Why it matters

The company expects the new partnership to significantly lower unit costs, which could improve the commercial viability and accessibility of the hormone-free contraceptive. Diversifying the supply chain is a key step toward scaling operations for the prescription product.

Evofem anticipates a reduction in unit costs of 40% or more through this new manufacturing partnership. PHEXX remains a hormone-free on-demand prescription contraceptive vaginal gel.

The players

Evofem Biosciences

A biopharmaceutical company based in San Diego that develops and markets innovative products for women's sexual and reproductive health.

FDA

The federal agency responsible for regulating new drug applications and ensuring the safety and efficacy of medical products in the United States.

The details

Evofem Biosciences is working to bolster its supply chain to meet demand for its flagship contraceptive product. The company plans to file a supplemental new drug application with the FDA to authorize this second source of production.

The company plans to submit a supplemental new drug application to the FDA in mid-2027.

Culture Shift

This move reflects a broader trend in the pharmaceutical sector where companies increasingly diversify their manufacturing to optimize costs and supply chain resilience. It signals a shift toward prioritizing long-term production efficiency for specialized women's health products.

Residents in the San Diego area may observe the company refining its production processes as it prepares for the 2027 regulatory submission. The goal of this expansion is to maintain the long-term availability and affordability of this prescription contraceptive option.

The takeaway

Securing additional manufacturing partners is a common strategy for pharmaceutical firms seeking to improve profit margins and product scalability. Consumers should note that these supply chain adjustments are often a precursor to long-term stability and cost management for medical products.